 |
50 Diseases |  |
65 Trials |
|
65 Trials |  |
4287 News |  |
| «12...3839404142434445464748...4950» |
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
New P2 trial, Metastases: VECODUE: Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients (clinicaltrials.gov) - Jul 21, 2017
P2, N=62, Not yet recruiting, Sponsor: Fondazione Melanoma Onlus
- | Biomarker, BRCA Biomarker, PARP Biomarker, Metastases: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (clinicaltrials.gov) - Jul 19, 2017
P2, N=1500, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
N=568 --> 1500
- | Zelboraf (vemurafenib) / Roche
Biomarker, New P2 trial, Metastases: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) (clinicaltrials.gov) - Jul 18, 2017
P2, N=49, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | LY3022855 / Eli Lilly
Enrollment open: LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma (clinicaltrials.gov) - Jul 17, 2017
P1/2, N=43, Recruiting, Sponsor: Dana-Farber Cancer Institute
N=568 --> 1500 Not yet recruiting --> Recruiting
- |||| Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: coBRIM: A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma (clinicaltrials.gov) - Jul 13, 2017
P3, N=495, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2017 --> May 2014
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial initiation date: ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma (clinicaltrials.gov) - Jul 13, 2017
P2, N=20, Recruiting, Sponsor: Inova Health Care Services
Trial primary completion date: Dec 2017 --> May 2014 Initiation date: Dec 2016 --> Jun 2017
- || Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma (clinicaltrials.gov) - Jul 11, 2017
P1b, N=68, Active, not recruiting, Sponsor: Genentech, Inc.
Initiation date: Dec 2016 --> Jun 2017 Trial primary completion date: Jun 2017 --> Nov 2018
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Enrollment open, Enrollment change, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 11, 2017
P1, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2017 --> Nov 2018 Active, not recruiting --> Recruiting | N=46 --> 35
- | Intron A (interferon ?-2b) / Merck (MSD), Biogen, Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zelboraf (vemurafenib) / Roche
Trial completion, Enrollment change, Trial primary completion date, Metastases: Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor (clinicaltrials.gov) - Jul 11, 2017
P1/2, N=6, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting | N=46 --> 35 Active, not recruiting --> Completed | N=71 --> 6 | Trial primary completion date: Jul 2018 --> Jul 2017
- | Tecentriq (atezolizumab) / Roche
Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker: Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer (clinicaltrials.gov) - Jul 7, 2017
P2, N=50, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=71 --> 6 | Trial primary completion date: Jul 2018 --> Jul 2017 Initiation date: Jun 2017 --> Sep 2017 | Trial primary completion date: Jun 2023 --> Sep 2023
- | Young TIL / National Cancer Institute
Trial primary completion date, Metastases: Vemurafenib and White Blood Cell Therapy for Advanced Melanoma (clinicaltrials.gov) - Jul 7, 2017
P1, N=12, Terminated, Sponsor: National Cancer Institute (NCI)
Initiation date: Jun 2017 --> Sep 2017 | Trial primary completion date: Jun 2023 --> Sep 2023 Trial primary completion date: Jun 2017 --> Jul 2016
- Zelboraf (vemurafenib) / Roche
Enrollment change, Trial primary completion date: A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants (clinicaltrials.gov) - Jul 7, 2017
P1, N=8, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2017 --> Jul 2016 Recruiting --> Active, not recruiting | N=16 --> 8 | Trial primary completion date: Nov 2016 --> Nov 2015 | N=16 --> 8 | Trial primary completion date: Nov 2016 --> Nov 2015
- ||| Zelboraf (vemurafenib) / Roche
Trial completion, Metastases: An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS) (clinicaltrials.gov) - Jun 21, 2017
P=N/A, N=339, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=16 --> 8 | Trial primary completion date: Nov 2016 --> Nov 2015 | N=16 --> 8 | Trial primary completion date: Nov 2016 --> Nov 2015 Active, not recruiting --> Completed
- Zelboraf (vemurafenib) / Roche
Trial completion, Enrollment change, Trial primary completion date: Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies (clinicaltrials.gov) - Jun 16, 2017
P1, N=6, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Completed | N=15 --> 6 | Trial primary completion date: Apr 2017 --> Aug 2016
- |||||||||| New P2/3 trial, Tumor mutational burden, IO Companion diagnostic, PD(L)-1 Biomarker, PD(L)-1 companion diagnostic, Metastases: BFAST: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jun 7, 2017
P2/3, N=580, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Enrollment change, Trial initiation date, Trial withdrawal, Metastases: Radiation Use During Vemurafenib Treatment (clinicaltrials.gov) - May 24, 2017
P1, N=0, Withdrawn, Sponsor: University of Utah
Recruiting --> Completed | N=15 --> 6 | Trial primary completion date: Apr 2017 --> Aug 2016 N=36 --> 0 | Initiation date: Jan 2017 --> Jun 2017 | Not yet recruiting --> Withdrawn
- | Zelboraf (vemurafenib) / Roche
Trial primary completion date: Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma (clinicaltrials.gov) - May 23, 2017
P2, N=17, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=36 --> 0 | Initiation date: Jan 2017 --> Jun 2017 | Not yet recruiting --> Withdrawn Trial primary completion date: Jun 2017 --> Mar 2018
- | Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: Study of Vemurafenib, Carboplatin, and Paclitaxel (clinicaltrials.gov) - May 22, 2017
P1, N=96, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2017 --> Mar 2018 Trial primary completion date: Jul 2018 --> Jul 2019
- | Zelboraf (vemurafenib) / Roche
Journal: Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. (Pubmed Central) - May 18, 2017
These results highlight that young patients with HCL have shorter responses to treatment and require more lines of therapy to maintain disease control, while attaining similar long-term survival. This has implications in the design of future clinical trials given our findings that secondary malignancies increase with more chemotherapy exposure.
- |||| Enrollment open, Trial initiation date, Heterogeneity, PD(L)-1 Biomarker: DARWIN II: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (clinicaltrials.gov) - May 18, 2017
P2, N=119, Recruiting, Sponsor: University College, London
This has implications in the design of future clinical trials given our findings that secondary malignancies increase with more chemotherapy exposure. Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> May 2017
- | Biomarker, New P2 trial, BRCA Biomarker, PARP Biomarker, Metastases: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (clinicaltrials.gov) - May 15, 2017
P2, N=568, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Enrollment open, PD(L)-1 Biomarker, IO biomarker: COWBOY: Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy (clinicaltrials.gov) - May 15, 2017
P2, N=200, Recruiting, Sponsor: Radboud University
Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> May 2017 Not yet recruiting --> Recruiting
- |||| Zelboraf (vemurafenib) / Roche
Trial primary completion date: BRIM8: A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma (clinicaltrials.gov) - May 12, 2017
P3, N=503, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2016 --> Jun 2017
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Enrollment closed, Enrollment change, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - May 11, 2017
P1, N=46, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2016 --> Jun 2017 Recruiting --> Active, not recruiting | N=33 --> 46
- | Tafinlar (dabrafenib) / Novartis, BeiGene, Zelboraf (vemurafenib) / Roche
Phase classification, Enrollment change, Trial termination, Trial primary completion date, Metastases: Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study (clinicaltrials.gov) - May 4, 2017
P2a/2b, N=8, Terminated, Sponsor: University Hospital Tuebingen
Recruiting --> Active, not recruiting | N=33 --> 46 Phase classification: P2a --> P2a/2b | N=42 --> 8 | Recruiting --> Terminated | Trial primary completion date: Jan 2016 --> Jan 2017; Second cohort not opened because Simon-Two_Step model failed
- ||| Cotellic (cobimetinib) / Exelixis, Roche
New trial, Metastases: MELANIS: A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic (clinicaltrials.gov) - May 4, 2017
P=N/A, N=200, Recruiting, Sponsor: Hoffmann-La Roche
- | Zelboraf (vemurafenib) / Roche
Journal: Oncofertility considerations in adolescents and young adults given a diagnosis of melanoma: Fertility risk of Food and Drug Administration-approved systemic therapies. (Pubmed Central) - Apr 26, 2017
Phase classification: P2a --> P2a/2b | N=42 --> 8 | Recruiting --> Terminated | Trial primary completion date: Jan 2016 --> Jan 2017; Second cohort not opened because Simon-Two_Step model failed Dermatologists have an opportunity to discuss fertility preservation, make appropriate referrals, and steward registries on reproductive outcomes for patients with melanoma.
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 21, 2017
P1, N=33, Recruiting, Sponsor: M.D. Anderson Cancer Center
Dermatologists have an opportunity to discuss fertility preservation, make appropriate referrals, and steward registries on reproductive outcomes for patients with melanoma. Trial primary completion date: Feb 2018 --> Feb 2019
- || Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma (clinicaltrials.gov) - Apr 17, 2017
P1, N=131, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Feb 2018 --> Feb 2019 Trial primary completion date: Dec 2016 --> Oct 2013
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
New trial: Prevention of Phototoxicities in Patients Undergoing Vemurafenib Treatment (clinicaltrials.gov) - Apr 10, 2017
P=N/A, N=222, Recruiting, Sponsor: Michele Sayag
- | Zelboraf (vemurafenib) / Roche
Phase classification, Enrollment change, Trial termination, Trial primary completion date, Combination therapy, Metastases: Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma (clinicaltrials.gov) - Apr 7, 2017
P1, N=3, Terminated, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2016 --> Oct 2013 Phase classification: P1/2 --> P1 | N=55 --> 3 | Suspended --> Terminated | Trial primary completion date: Jul 2017 --> Jan 2014; Adverse Events
- | Votrient (pazopanib) / Novartis, sunitinib / Generic mfg., Zelboraf (vemurafenib) / Roche
Enrollment closed, Trial primary completion date, Metastases: ICK: Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=43, Active, not recruiting, Sponsor: VU University Medical Center
Phase classification: P1/2 --> P1 | N=55 --> 3 | Suspended --> Terminated | Trial primary completion date: Jul 2017 --> Jan 2014; Adverse Events Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2017
- | LY3022855 / Eli Lilly
New P1/2 trial: LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma (clinicaltrials.gov) - Apr 5, 2017
P1/2, N=43, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- CDX-3379 / Celldex
Trial completion: Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 (clinicaltrials.gov) - Apr 4, 2017
P1, N=7, Completed, Sponsor: Celldex Therapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2017 Active, not recruiting --> Completed
- | Xalkori (crizotinib) / Pfizer, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations (clinicaltrials.gov) - Mar 29, 2017
P1, N=183, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Feb 2018 --> Feb 2019
- | Zyclara (imiquimod) / Mochida, Mylan, Bausch Health, Zelboraf (vemurafenib) / Roche
Journal: Successful treatment of multiple vemurafenib-induced keratoacanthomas by topical application of imiquimod cream: Confirmation of clinical clearance by dermoscopy. (Pubmed Central) - Mar 22, 2017
KAs successfully treated with topical application of imiquimod cream and clearance of these lesions was further confirmed by dermoscopic examination. Topical imiquimod can be an effective treatment option for the noninvasive management of multiple KAs induced by vemurafenib treatment.
- Zelboraf (vemurafenib) / Roche
Trial primary completion date: A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State (clinicaltrials.gov) - Mar 20, 2017
P1, N=32, Recruiting, Sponsor: Genentech, Inc.
Topical imiquimod can be an effective treatment option for the noninvasive management of multiple KAs induced by vemurafenib treatment. Trial primary completion date: Jan 2018 --> Nov 2018
- | Zelboraf (vemurafenib) / Roche
Trial primary completion date: BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia (clinicaltrials.gov) - Mar 17, 2017
P2, N=36, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jan 2018 --> Nov 2018 Trial primary completion date: Oct 2017 --> Oct 2018
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zelboraf (vemurafenib) / Roche
Enrollment change, Trial termination, IO biomarker: Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma (clinicaltrials.gov) - Mar 13, 2017
P2, N=6, Terminated, Sponsor: Massachusetts General Hospital
Trial primary completion date: Oct 2017 --> Oct 2018 N=49 --> 6 | Active, not recruiting --> Terminated; changes in available treatments for melanoma
- | Enrollment closed, Trial primary completion date: MetAction: N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (clinicaltrials.gov) - Mar 13, 2017
P2, N=50, Active, not recruiting, Sponsor: Oslo University Hospital
N=49 --> 6 | Active, not recruiting --> Terminated; changes in available treatments for melanoma Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Aug 2017
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Enrollment change, Trial termination, Trial primary completion date, IO biomarker, Metastases: The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma (clinicaltrials.gov) - Mar 6, 2017
P2, N=5, Terminated, Sponsor: Georgetown University
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Aug 2017 N=15 --> 5 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Aug 2016; Recruitment difficulties.
- Zelboraf (vemurafenib) / Roche
Trial primary completion date: Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study (clinicaltrials.gov) - Mar 1, 2017
P=N/A, N=12, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=15 --> 5 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Aug 2016; Recruitment difficulties. Trial primary completion date: May 2017 --> May 2018
- | Zelboraf (vemurafenib) / Roche
Enrollment open, Metastases: Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer (clinicaltrials.gov) - Feb 23, 2017
P2, N=22, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: May 2017 --> May 2018 Active, not recruiting --> Recruiting
- || Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma (clinicaltrials.gov) - Feb 23, 2017
P1b, N=70, Active, not recruiting, Sponsor: Genentech, Inc.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Jun 2017
- | Zelboraf (vemurafenib) / Roche
Enrollment closed, Metastases: Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer (clinicaltrials.gov) - Feb 17, 2017
P2, N=23, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Jun 2017 Recruiting --> Active, not recruiting
- | Journal: Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. (Pubmed Central) - Feb 16, 2017
Pevonedistat additionally synergized with the BRAF kinase inhibitor PLX4720 to inhibit BRAF melanoma, and suppressed PLX4720-resistant melanoma cells...Pevonedistat also synergizes with vemurafenib in vivo and suppresses vemurafenib-resistant melanoma cells. These findings show a significant promise for targeting CRL4(CDT2) therapeutically.
- Intron A (interferon ?-2b) / Merck (MSD), Biogen, Zelboraf (vemurafenib) / Roche
Enrollment closed, Phase classification, Enrollment change, Trial primary completion date, Metastases: Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma (clinicaltrials.gov) - Feb 11, 2017
P1, N=7, Active, not recruiting, Sponsor: John Kirkwood
These findings show a significant promise for targeting CRL4(CDT2) therapeutically. Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=63 --> 7 | Trial primary completion date: Sep 2017 --> Jan 2017
- |||| pacmilimab (CX-072) / CytomX
Enrollment open, Combination therapy, Monotherapy, Metastases: PROCLAIM-072 : PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas (clinicaltrials.gov) - Feb 4, 2017
P1/2, N=150, Recruiting, Sponsor: CytomX Therapeutics
Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=63 --> 7 | Trial primary completion date: Sep 2017 --> Jan 2017 Not yet recruiting --> Recruiting
- |||||| Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, PD(L)-1 Biomarker, Metastases: IMspire150: A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma (clinicaltrials.gov) - Jan 26, 2017
P3, N=500, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: VEMUPLINT: Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation (clinicaltrials.gov) - Jan 19, 2017
P1/2, N=48, Recruiting, Sponsor: Fondazione Melanoma Onlus
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017